Tenaya Therapeutics, Inc. (TNYA)

Market Cap	184.16M
Revenue (ttm)	n/a
Net Income (ttm)	-99.62M
Shares Out	162.98M
EPS (ttm)	-0.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,982,597
Open	1.110
Previous Close	1.100
Day's Range	1.110 - 1.250
52-Week Range	0.360 - 4.010
Beta	3.01
Analysts	Strong Buy
Price Target	8.60 (+661.06%)
Earnings Date	Aug 6, 2025

About TNYA

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company’s lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved eject...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 97
• Stock Exchange: NASDAQ
• Ticker Symbol: TNYA
• Website: https://www.tenayatherapeutics.com

Analyst Summary

According to 5 analysts, the average rating for TNYA stock is "Strong Buy." The 12-month stock price target is $8.6, which is an increase of 661.06% from the latest price.

Price Target

$8.6

(661.06% upside)

Analyst Consensus: Strong Buy